Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Scilex Holding CoSCLX · Entity 7345 | Director · CFO, COO and Secretary | April 17, 2026 | April 20, 2026 |
| Semnur Pharmaceuticals, Inc.SMNR · Entity 6623 | See Remarks | September 22, 2025 | September 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Scilex Holding Co
Report date April 17, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2029-06-18 | Direct | 650,000 |
Reported balance
After 2026-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-17 · Purchase · Acquired 650,000 · Balance 650,000 |
Semnur Pharmaceuticals, Inc.
Report date September 22, 2025 · Filed September 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2034-08-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-09-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The option vests in equal monthly installments of 1/48th per month. Except as described in the next sentence, the option is currently exercisable pursuant to the approval by shareholders of the Issuer of the option exchange on September 3, 2025, as described in the Issuer's Registration Statement on Form S-4 filed with the Securities and Exchange Commission (File No. 333-283019), which became effective on August 12, 2025. Until the date on which all payments and all obligations under that certain Senior Secured Promissory Note, dated as of September 21, 2023, issued by Scilex Holding Company (the controlling stockholder of the Issuer) to Oramed Pharmaceuticals, Inc., a Delaware corporation, F2: (Continued from footnote 1) have been paid in full in cash, the options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Issuer or any of its respective current and future subsidiaries, successors and assigns. F3: The option expires ten years from the date of issuance, unless earlier terminated in accordance with the terms of the Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan. F4: Represents shares of the Issuer's Common Stock underlying the option, for which (except as described above) the option became exercisable in connection with a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, a wholly owned subsidiary of the Issuer, and Semnur, Inc. (f/k/a Semnur Pharmaceuticals, Inc.) ("Old Semnur"), which became a wholly owned subsidiary of the Issuer upon completion of the Business Combination. Upon consummation of the Business Combination, the reporting person's option to purchase shares of common stock of Old Semnur was exchanged for an option to purchase shares of common stock of the Issuer at an exchange ratio of 1.25 to 1. The number of shares reflects the application of the exchange ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments of 1/48th per month. Except as described in the next sentence, the option is currently exercisable pursuant to the approval by shareholders of the Issuer of the option exchange on September 3, 2025, as described in the Issuer's Registration Statement on Form S-4 filed with the Securities and Exchange Commission (File No. 333-283019), which became effective on August 12, 2025. Until the date on which all payments and all obligations under that certain Senior Secured Promissory Note, dated as of September 21, 2023, issued by Scilex Holding Company (the controlling stockholder of the Issuer) to Oramed Pharmaceuticals, Inc., a Delaware corporation,
F2: (Continued from footnote 1) have been paid in full in cash, the options will not be or become exercisable, eligible for exchange, redemption or repurchase, eligible to participate in any dividends or distributions (including the proceeds of any corporate transaction) or have any voting rights in respect of, among other things, the Issuer or any of its respective current and future subsidiaries, successors and assigns.
F3: The option expires ten years from the date of issuance, unless earlier terminated in accordance with the terms of the Semnur Pharmaceuticals, Inc. 2024 Stock Option Plan.
F4: Represents shares of the Issuer's Common Stock underlying the option, for which (except as described above) the option became exercisable in connection with a business combination (the "Business Combination") which was effectuated in accordance with the terms of the Agreement and Plan of Merger, dated as of August 30, 2024 (as amended on April 16, 2025 and July 22, 2025), by and among the Issuer, a wholly owned subsidiary of the Issuer, and Semnur, Inc. (f/k/a Semnur Pharmaceuticals, Inc.) ("Old Semnur"), which became a wholly owned subsidiary of the Issuer upon completion of the Business Combination. Upon consummation of the Business Combination, the reporting person's option to purchase shares of common stock of Old Semnur was exchanged for an option to purchase shares of common stock of the Issuer at an exchange ratio of 1.25 to 1. The number of shares reflects the application of the exchange ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2026 Filed Apr 20, 2026 12:56 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseWarrant (right to buy) · Derivative | 650,000 | $0.15 Strike: $1.20 | $99,970.00 |
DisclosureSEC source: 0001193125-26-162857 · ownership.xml · derivative · entry 1 Ma Stephen Hoi · CIK 0001954364 · Director · CFO, COO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2029-06-18 Read SEC document |
| October 08, 2025 Filed Oct 9, 2025 12:45 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantIncentive Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001193125-25-235245 · ownership.xml · derivative · entry 1 Ma Stephen Hoi · CIK 0001954364 · Director · CFO and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-10-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Notwithstanding the preceding sentence, the shares of Common Stock subject to the Option will not be exercisable until such date as the Issuer's outstanding indebtedness under the Senior Secured Promissory Note issued by the Issuer to Oramed Pharmaceuticals, Inc. on September 21, 2023 and the Tranche B Senior Secured Convertible Notes issued by the Issuer to each of Oramed Pharmaceuticals, Inc., Nomis Bay Ltd., 3i LP and BPY Limited, has been repaid in full. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 15:09 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 6,700 | $0.97 | $6,499.00 |
DisclosureSEC source: 0000950170-24-115199 · ownership.xml · nonDerivative · entry 1 Ma Stephen Hoi · CIK 0001954364 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,840 F1 · shares: Open market purchase by the reporting person of 6,700 shares of common stock, par value $0.0001 per share. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 20:54 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionNonstatutory Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-24-075674 · ownership.xml · derivative · entry 2 Ma Stephen Hoi · CIK 0001954364 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 2,000 shares Expires 2033-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 20, 2024 20:54 UTC | Scilex Holding Co SCLX · Entity 7345 | Exercise / conversionCommon Stock | 2,000 | $1.41 | $2,820.00 |
DisclosureSEC source: 0000950170-24-075674 · ownership.xml · nonDerivative · entry 1 Ma Stephen Hoi · CIK 0001954364 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: 1/48th of the number of shares subject to the option vested and shall vest on a monthly basis following the grant date, which was October 4, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| May 17, 2024 Filed May 17, 2024 20:29 UTC | Scilex Holding Co SCLX · Entity 7345 | PurchaseCommon Stock | 14,140 | $0.88 | $12,443.20 |
DisclosureSEC source: 0000950170-24-061690 · ownership.xml · nonDerivative · entry 1 Ma Stephen Hoi · CIK 0001954364 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,140 F1 · shares: Open market purchase by the reporting person of 14,140 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions at the same purchase price. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 01:24 UTC | Scilex Holding Co SCLX · Entity 7345 | GrantNonstatutory Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0000950170-23-052254 · ownership.xml · derivative · entry 1 Ma Stephen Hoi · CIK 0001954364 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-10-04 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.